Study aims to measure vaccine’s true impact on over-65s

The Santiago Health Institute (IDIS) and the Ministry of Health of the Government of Galicia have launched an innovative study aimed at measuring The real impact of the flu vaccine on those aged 65 to 79. Specifically, the study will assess the relative effectiveness of the standard-dose vaccine versus Sanofi’s high-load Efluelda vaccine in reducing the risk of hospitalization due to influenza or pneumonia as the primary variable of the study.

This work will also take into account As secondary variables, hospitalizations due to cardiopulmonary disease, influenza, or pneumonia, as well as hospitalizations and mortality from any cause.

The study, which the laboratory reports is the first of its kind in Spain, combines two methods: randomization and real-life data collection. On one hand, randomization will be used to assign participants to the standard-dose vaccine or the high-load vaccine. This ensures that the observed effects are due to the vaccine administered. On the other hand, the evaluation of the results will be based on Subsequent health records will help determine how many patients were admitted and why.

Federico Martinón Torres, coordinator of the vaccine research group at the Santiago Health Institute and sponsor of the GalFlu study, said, “In Galicia, high-load vaccines are already routinely administered to people over 80 years old and have proven to be more effective; this research showsWe want to evaluate the benefit in people aged 65 to 79 years, and if the hypothesis is confirmed, we will provide greater protection for this group. People who have a weakened immune system are considered vulnerable and are at a higher risk of serious complications after getting the flu. “

This real-life study requires participation More than 114,000 people aged 65 to 79 will receive the next two flu vaccination campaigns Implemented by the Ministry of Galicia.

this is about Largest individual randomized study conducted by Spanish public health authorities It is expected to provide strong evidence for important variables, such as reductions in influenza-induced hospitalization and mortality.Older people: greater risk of influenza and its complications

Reduce hospitalization

A recent study conducted in Spain reveals the estimated impact of seasonal influenza in our country over the ten years 2008 to 2018.Among the key findings, the huge burden of influenza-related hospitalizations, particularly in Spain, stands outPatients over 65 years old accounted for 65.6% of total hospitalizations and 81.1% of direct costs. Additionally, hospitalization rates for respiratory and cardiovascular disease diagnoses are approximately 4.5 times higher in this age group than in other groups.

The hospitalization variable is of importance in health systems because it reflects not only the severity of influenza infection but also the severity of its consequences. Hospitalization due to influenza not only imposes a significant financial burden on medical resources and related costs, But it can also lead to patients losing their autonomy.

Particularly for older adults, hospitalization may result in reduced independence and mobility, affecting quality of life and long-term care resources. This link between hospitalization and loss of autonomy highlights the importance of preventive strategies, such as vaccination, to avoid hospitalization and its consequences for vulnerable populations.

To meet this challenge, Multiple independent organizations recommend that people over 65 receive high-dose vaccinesbecause they contain a higher concentration of antigen (4 times more than a standard dose), which can stimulate a more powerful immune response.

These high-load vaccines are designed to better protect against influenza infection, Relative efficacy increased by 24.2% compared to standard dose vaccine; and related complications, hospitalizations for pneumonia were reduced by 27.8%, hospitalizations for cardiovascular complications were reduced by 16.7%, and hospitalizations for all causes were reduced by 8.2%5.

Likewise, in the DanFlu-16 trial, the trial evaluated the possibility of conducting a randomized study based on real-world data to investigate the effectiveness of a high-load vaccine versus a regular vaccine.Standard dose, results show Efluelda vaccine Associated with a 64.4% reduction in hospitalizations for influenza or pneumonia among people aged 65 to 79, compared to standard dose vaccines. DanFlu-1 has allowed the launch of a large-scale randomized study that will be conducted during the next two anti-influenza campaigns in Galicia.

Source link

Leave a Comment